Basal Analog denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for basal analog are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Basal Analog Insulin as Non-Formulary

A non-formulary denial means the specific basal analog insulin prescribed is not on UnitedHealthcare's approved drug list for your plan. UHC's formularies typically cover at least one basal analog insulin, but the plan may prefer a different brand, a specific biosimilar, or a particular delivery device over the one your prescriber selected. The denial may also result from a tier placement that requires prior authorization or step therapy before coverage is extended to the prescribed product.

## Why This Denial Is Appealable

Plans are required to grant formulary exceptions when a covered alternative is clinically inappropriate for a specific patient. If your prescriber can document that the formulary alternative is contraindicated, has been tried and failed, or is clinically inferior for your individual situation — based on factors such as tolerability, injection device requirements, or titration characteristics — a formulary exception appeal is well-supported. Verify whether UHC's published exception criteria match your clinical circumstances.

## Your Federal Appeal Rights

• Internal appeal / formulary exception: File a formulary exception request — many plans have a separate, faster track for this. Simultaneously or subsequently file a standard internal appeal.
• External review (ACA §2719 / ERISA §503): After exhausting the internal process, an Independent Review Organization can independently evaluate whether the formulary exception should be granted. The external-review window is approximately four months from final denial — check your denial letter for the binding deadline.
• Expedited option: Available when the standard timeline poses a risk to your health; insulin access commonly qualifies.

## Documents to Gather

1. Diagnosis confirmation — chart notes confirming insulin-requiring diabetes. 2. Formulary alternative trial history — if you previously tried the preferred formulary insulin and had a clinical problem, document the dates, the issue, and why you stopped. 3. Clinical rationale for the specific product — a prescriber note explaining why the non-formulary agent was selected over the formulary alternative (e.g., device compatibility, titration profile, patient-specific clinical factors). 4. Prescriber formulary-exception letter — addressed to UnitedHealthcare, stating the medical necessity of the specific prescribed product and why the formulary alternative is insufficient.

## Criteria-Mapping Structure

Obtain UnitedHealthcare's formulary exception criteria and the plan's drug list. For each exception requirement:

| Exception Criterion | Your Supporting Evidence | |---|---| | Formulary alternative tried and failed | [dates, product, reason for failure] | | Formulary alternative clinically inappropriate | [prescriber statement of specific contraindication or clinical reason] | | Prescribed product is medically necessary | [prescriber letter with clinical rationale] |

Match each criterion to dated, specific chart facts. Formulary exception appeals succeed most often when the prescriber's letter directly addresses the plan's own exception criteria rather than providing a general medical-necessity narrative.